About insitro inc
19 articles with insitro inc
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
insitro and Genomics England Announce Partnership to Provide Multimodal Search Capabilities and Empower Data Exploration and Derivation of Novel Insights
As part of the collaboration, insitro will deploy its machine-learning capabilities on Genomics England’s histopathology images and accompanying genetic data to learn a multimodal representation that captures the fine grained semantic structure in this high-dimensional clinical data.
insitro Announces Leadership Team Expansion to Support Advancement of Machine Learning Enabled Drug Discovery and Development Efforts
insitro, a machine learning-driven drug discovery and development company, today announced the expansion of its leadership team with the appointments of several industry leaders.
BioSpace Movers & Shakers, Sept. 10
9/10/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
With the adaptation of new technologies, tech executives are finding new homes in biotech and the life sciences.
Yesterday marked the close of three new financing rounds in the biotech space. Although none of today’s are that large, there is still plenty of money on the move. Here’s a look.
Several biotech companies have announced closings of million-dollar financing rounds Monday, with Cambridge, Mass.-based cell and gene therapy company ElevateBio leading the pack. ElevateBio announced it raised $525 million in a Series C financing round, which the company says should help expand ...
insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia insitro to Receive $50 Million in Upfront Cash with Total Potential Deal Value Over $2.1 Billion Collaboration to Advance Targets and Therapeutic Candidates SAN FRANCISCO--( BUSINESS WIRE )-- insitro, a machine-learning driven drug discovery and development compan
Through this collaboration, Insitro will utilize its proprietary platform, Insitro Human (ISH), to create induced pluripotent stem cell (iPSC) derived disease models for both diseases.
Bay Area-based insitro snapped up neighboring Haystack Sciences to bolster its machine-learning drug discovery programs with that company’s higher resolution dataset-producing technology.
BioSpace Movers & Shakers, Oct. 2
10/2/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
insitro Adds Biopharma Industry Leader Roger Perlmutter as First Independent Board Member
insitro, a machine-learning driven drug discovery and development company, announced the appointment of Roger Perlmutter, M.D., Ph.D., executive vice president and president of Merck Research Laboratories, Merck’s global R&D organization, as the company’s first independent board director.
The funding will be used to continue to build the company’s technology and automation, which enable data generation at a larger scale. This will expand Insitro’s ability to create predictive models of human disease.
BioSpace Movers & Shakers, Dec. 6
12/6/2019Pharma and biotech companies strengthen their leadership teams and boards with this week's hires.
insitro Expands Leadership Team with Appointment of Serafim Batzoglou as Chief Data Officer
Dr. Batzoglou brings to insitro more than two decades of expertise in machine learning and computational genomics as a former Professor of Computer Science at Stanford University and Vice President of Applied and Computational Biology at Illumina.
insitro Announces Key Leadership Appointments
Matthew Rasmussen, Ph.D., Appointed as Vice President, Data Engineering Duane Valz Appointed as General Counsel
insitro Strengthens Executive Leadership Team with Key Appointments
insitro, a machine-learning driven drug discovery and development company, today announced two key leadership appointments.
Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis
Gilead Sciences Inc. and insitro announced that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis.
Under terms of the deal, Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development against these targets.